Student Research Committee, Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
Halal Research Center of IRI, FDA, Tehran, Iran.
Phytother Res. 2019 Apr;33(4):871-880. doi: 10.1002/ptr.6287. Epub 2019 Mar 5.
Dyslipidemia is a leading cause of endothelial dysfunction and cardiovascular disease. Several studies used silymarin as an herbal supplement in hyperlipidemic subjects. The aim of the present systematic review and meta-analysis was to examine the effect of silymarin supplementation on blood lipids. PubMed, Scopus, Ovid (Cochrane library), ISI Web of Science, and Google Scholar were systematically searched until March 2018 to find intervention studies that examined the impact of silymarin supplementation on blood lipids in adults. Changes in blood lipids and potential sources of between-study variation were extracted. We run a subgroup analysis to determine potential sources of inter-study heterogeneity. Ten clinical trials fulfilled the eligibility criteria. Meta-analysis indicated that silymarin supplementation in combination with other treatments (not silymarin alone) reduced total cholesterol (change: -25.45 mg/dl; 95% confidence interval [CI] [-47.89, -3.01 mg/dl]) and low-density lipoprotein (change: -28.25 mg/dl; 95% CI [-53.09, -3.42 mg/dl]). Also, silymarin increased high-density lipoprotein concentration (change: 4.82 mg/dl; 95% CI [2.01, 7.63 mg/dl]). Blood concentration of triglyceride was significantly after silymarin supplementation in comparison with controls (change: -22.55 mg/dl; 95% CI [-44.32, -0.78 mg/dl]). Present systematic review and meta-analysis revealed that silymarin supplementation in combination with other treatments had a favorable effect on blood lipids.
血脂异常是内皮功能障碍和心血管疾病的主要原因。有几项研究将水飞蓟素作为一种草药补充剂用于高脂血症患者。本系统评价和荟萃分析的目的是研究水飞蓟素补充剂对血脂的影响。系统检索了 PubMed、Scopus、Ovid（Cochrane 图书馆）、ISI Web of Science 和 Google Scholar，以查找截至 2018 年 3 月的干预研究，这些研究检查了水飞蓟素补充剂对成年人血脂的影响。提取了血脂变化和潜在的研究间变异性来源。我们进行了亚组分析，以确定研究间异质性的潜在来源。有 10 项临床试验符合入选标准。荟萃分析表明，水飞蓟素与其他治疗方法（而非单独使用水飞蓟素）联合使用可降低总胆固醇（变化：-25.45mg/dl；95%置信区间[-47.89，-3.01mg/dl]）和低密度脂蛋白（变化：-28.25mg/dl；95%置信区间[-53.09，-3.42mg/dl]）。此外，水飞蓟素增加了高密度脂蛋白浓度（变化：4.82mg/dl；95%置信区间[2.01，7.63mg/dl]）。与对照组相比，水飞蓟素补充后血液中甘油三酯浓度显著降低（变化：-22.55mg/dl；95%置信区间[-44.32，-0.78mg/dl]）。本系统评价和荟萃分析表明，水飞蓟素与其他治疗方法联合使用对血脂有有利影响。
